Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicentre, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

Next Previous
Trial Profile

A Phase 2, Multicentre, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; SCIB 1 (Primary) ; Ipilimumab; Nivolumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SCOPE study
  • Sponsors Scancell

    • Most Recent Events

    • 30 Jan 2024 According to a Scancell media release, addition of iSCIB1+ to the SCOPE trial has been approved by the MHRA. Recruitment in this third cohort is expected to start in Q1 2024 with early data available in Q3 2024. iSCIB1+ includes additional melanoma-specific epitopes so it has the potential to be even more effective in a broader patient population.
    • 30 Jan 2024 According to a Scancell media release, recruitment in the second stage is expected to be complete in Q1 2024 with highly anticipated data available in Q3 2024.
    • 01 Nov 2023 According to a Scancell media release, data from the first stage in its Phase 2 SCOPE trial, has been selected for a poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place on 1-5 November 2023 in San Diego, CA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top